The New England journal of medicine, 2021-01, Vol.384 (3), p.229-237
- Chen, Peter
- Nirula, Ajay
- Heller, Barry
- Gottlieb, Robert L
- Boscia, Joseph
- Morris, Jason
- Huhn, Gregory
- Cardona, Jose
- Mocherla, Bharat
- Stosor, Valentina
- Shawa, Imad
- Adams, Andrew C
- Van Naarden, Jacob
- Custer, Kenneth L
- Shen, Lei
- Durante, Michael
- Oakley, Gerard
- Schade, Andrew E
- Sabo, Janelle
- Patel, Dipak R
- Klekotka, Paul
- Skovronsky, Daniel M
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Chen, Peter
- Nirula, Ajay
- Heller, Barry
- Gottlieb, Robert L
- Boscia, Joseph
- Morris, Jason
- Huhn, Gregory
- Cardona, Jose
- Mocherla, Bharat
- Stosor, Valentina
- Shawa, Imad
- Adams, Andrew C
- Van Naarden, Jacob
- Custer, Kenneth L
- Shen, Lei
- Durante, Michael
- Oakley, Gerard
- Schade, Andrew E
- Sabo, Janelle
- Patel, Dipak R
- Klekotka, Paul
- Skovronsky, Daniel M
- Titel
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- Ist Teil von
- The New England journal of medicine, 2021-01, Vol.384 (3), p.229-237
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%).
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2029849Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7646625
- Format
- –
- Schlagworte
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Antibodies, Monoclonal, Humanized - administration & dosage, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Neutralizing - administration & dosage, Antibodies, Neutralizing - adverse effects, Asymptomatic, Clinical outcomes, Coronaviridae, Coronaviruses, COVID-19, COVID-19 - drug therapy, COVID-19 - virology, Disease, Dose-Response Relationship, Drug, Double-Blind Method, Emergency medical care, Female, Hospitalization - statistics & numerical data, Humans, Immunologic Factors - administration & dosage, Immunologic Factors - adverse effects, International organizations, Intravenous administration, Male, Medical research, Middle Aged, Monoclonal antibodies, Original, Outpatients, Pandemics, Patients, Placebos, Reverse Transcriptase Polymerase Chain Reaction, Ribonucleic acid, Risk factors, RNA, RNA, Viral - blood, SARS-CoV-2 - genetics, SARS-CoV-2 - isolation & purification, Severe acute respiratory syndrome coronavirus 2, Severity of Illness Index, Statistical analysis, Viral Load - drug effects, Young Adult